Dynamics of chronic myeloid leukaemia

被引：0
|
作者：
Franziska Michor
Timothy P. Hughes
Yoh Iwasa
Susan Branford
Neil P. Shah
Charles L. Sawyers
Martin A. Nowak
机构：
[1] Harvard University,Program for Evolutionary Dynamics, Department of Organismic and Evolutionary Biology, Department of Mathematics
[2] Institute of Medical and Veterinary Science,Department of Biology
[3] Kyushu University,Howard Hughes Medical Institute, Molecular Biology Institute, Department of Urology, Department of Medical and Molecular Pharmacology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine
[4] Department of Medicine,undefined
[5] University of California,undefined
来源：
Nature | 2005年 / 435卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Chronic myeloid leukaemia is associated with the oncogene BCR-ABL. The tyrosine kinase inhibitor imatinib (Gleevec), in the news as the first molecularly targeted anticancer drug, acts by impairing the function of this oncogene. A study of 169 patients receiving imatinib followed the kinetics of BCR-ABL in order to develop a mathematical model of the in vivo kinetics of a cancer. Imatinib reduced the rate of leukaemic cell production, but did not appear to deplete a population of leukaemic stem cells. The model also indicates when multiple drug therapy might be more effective than imatinib alone.
引用
收藏
页码：1267 / 1270
页数：3
相关论文
共 50 条
12345